Lyell Immunopharma Inc. (NASDAQ: LYEL) announced that the first patient has been dosed in its PiNACLE – H2H Phase 3 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE